Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

NCT02952586

Last updated date
Study Location
Highlands Oncology Group
Fayetteville, Arkansas, 72703, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Squamous Cell Carcinoma of the Head and Neck
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Squamous Cell Carcinoma of the Head and NeckStudy To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) NCT02952586
  1. Fayetteville, Arkansas
  2. Rogers, Arkansas
  3. Anaheim, California
  4. Bakersfield, California
  5. Beverly Hills, California
  6. Beverly Hills, California
  7. Chula Vista, California
  8. Corona, California
  9. Corona, California
  10. Downey, California
  11. Duarte, California
  12. Duarte, California
  13. Fountain Valley, California
  14. Glendale, California
  15. La Jolla, California
  16. La Jolla, California
  17. La Jolla, California
  18. Lancaster, California
  19. Long Beach, California
  20. Los Angeles, California
  21. Los Angeles, California
  22. Los Angeles, California
  23. Lynwood, California
  24. Montebello, California
  25. Orange, California
  26. Riverside, California
  27. San Diego, California
  28. Santa Ana, California
  29. South Pasadena, California
  30. Torrance, California
  31. West Covina, California
  32. Whittier, California
  33. Whittier, California
  34. Aurora, Colorado
  35. Aurora, Colorado
  36. Aurora, Colorado
  37. Aurora, Colorado
  38. Aurora, Colorado
  39. Aurora, Colorado
  40. Denver, Colorado
  41. Denver, Colorado
  42. Parker, Colorado
  43. Coral Gables, Florida
  44. Deerfield Beach, Florida
  45. Hialeah, Florida
  46. Hollywood, Florida
  47. Hollywood, Florida
  48. Lakeland, Florida
  49. Miami, Florida
  50. Pembroke Pines, Florida
  51. Pembroke Pines, Florida
  52. Plantation, Florida
  53. Tampa, Florida
  54. Flossmoor, Illinois
  55. Harvey, Illinois
  56. Harvey, Illinois
  57. Tinley Park, Illinois
  58. Lafayette, Indiana
  59. Overland Park, Kansas
  60. Ashland, Kentucky
  61. Louisville, Kentucky
  62. Louisville, Kentucky
  63. Louisville, Kentucky
  64. Louisville, Kentucky
  65. Louisville, Kentucky
  66. Louisville, Kentucky
  67. Louisville, Kentucky
  68. Prestonsburg, Kentucky
  69. Baltimore, Maryland
  70. Baltimore, Maryland
  71. Baltimore, Maryland
  72. Boston, Massachusetts
  73. Detroit, Michigan
  74. Detroit, Michigan
  75. Farmington Hills, Michigan
  76. Lansing, Michigan
  77. Corinth, Mississippi
  78. Columbia, Missouri
  79. Columbia, Missouri
  80. Creve Coeur, Missouri
  81. Kansas City, Missouri
  82. Saint Louis, Missouri
  83. Saint Louis, Missouri
  84. Saint Louis, Missouri
  85. Saint Louis, Missouri
  86. Saint Peters, Missouri
  87. Omaha, Nebraska
  88. Omaha, Nebraska
  89. Omaha, Nebraska
  90. Basking Ridge, New Jersey
  91. Hackensack, New Jersey
  92. Hackensack, New Jersey
  93. Middletown, New Jersey
  94. Montvale, New Jersey
  95. Albuquerque, New Mexico
  96. Albuquerque, New Mexico
  97. Bronx, New York
  98. Bronx, New York
  99. Commack, New York
  100. Harrison, New York
  101. New York, New York
  102. New York, New York
  103. New York, New York
  104. New York, New York
  105. New York, New York
  106. New York, New York
  107. New York, New York
  108. New York, New York
  109. Stony Brook, New York
  110. Stony Brook, New York
  111. Uniondale, New York
  112. Charlotte, North Carolina
  113. Charlotte, North Carolina
  114. Winston-Salem, North Carolina
  115. Cleveland, Ohio
  116. Oklahoma City, Oklahoma
  117. Oklahoma City, Oklahoma
  118. Oklahoma City, Oklahoma
  119. Allentown, Pennsylvania
  120. Allentown, Pennsylvania
  121. Allentown, Pennsylvania
  122. Bethlehem, Pennsylvania
  123. Gettysburg, Pennsylvania
  124. Harrisburg, Pennsylvania
  125. Harrisburg, Pennsylvania
  126. Mechancisburg, Pennsylvania
  127. Philadelphia, Pennsylvania
  128. Pittsburgh, Pennsylvania
  129. Pittsburgh, Pennsylvania
  130. Pittsburgh, Pennsylvania
  131. Charleston, South Carolina
  132. Charleston, South Carolina
  133. Charleston, South Carolina
  134. Charleston, South Carolina
  135. Charleston, South Carolina
  136. Charleston, South Carolina
  137. Charleston, South Carolina
  138. Easley, South Carolina
  139. Greenville, South Carolina
  140. Greenville, South Carolina
  141. Greer, South Carolina
  142. Seneca, South Carolina
  143. Spartanburg, South Carolina
  144. Germantown, Tennessee
  145. Memphis, Tennessee
  146. Nashville, Tennessee
  147. Nashville, Tennessee
  148. El Paso, Texas
  149. El Paso, Texas
  150. El Paso, Texas
  151. Galveston, Texas
  152. Galveston, Texas
  153. Houston, Texas
  154. Houston, Texas
  155. Houston, Texas
  156. League City, Texas
  157. Murray, Utah
  158. Salt Lake City, Utah
  159. Seattle, Washington
  160. Seattle, Washington
  161. Seattle, Washington
  162. Camperdown, New South Wales
  163. Camperdown, New South Wales
  164. Camperdown, New South Wales
  165. Camperdown, New South Wales
  166. St Leonards, New South Wales
  167. St Leonards, New South Wales
  168. Wollongong, New South Wales
  169. Wollongong, New South Wales
  170. Geelong, Victoria
  171. Heidelberg, Victoria
  172. Heidelburg, Victoria
  173. Linz,
  174. Brussels,
  175. Charleroi,
  176. Haine Saint Paul,
  177. Namur,
  178. Wilrijk,
  179. Quebec,
  180. Beijing, Beijing
  181. Fuzhou, Fujian
  182. Guangzhou, Guangdong
  183. Guangzhou, Guangdong
  184. Nanning, Guangxi
  185. Haikou, Hainan
  186. Harbin, Heilongjiang
  187. Zhengzhou, Henan
  188. Wuhan, Hubei
  189. Wuhan, Hubei
  190. Changsha, Hunan
  191. Shenyang, Liaoning
  192. Shanghai, Shanghai
  193. Shanghai, Shanghai
  194. Chengdu, Sichuan
  195. Tianjin, Tianjin
  196. Tianjin, Tianjin
  197. Haerbin,
  198. Angers cedex 02,
  199. Avignon Cedex 9,
  200. Avignon cedex 9,
  201. Avingon Cedex 9,
  202. Bordeaux CEDEX,
  203. Bordeaux,
  204. Bordeaux,
  205. Brest,
  206. Brest,
  207. Brest,
  208. Levallois-Perret,
  209. Montpellier cedex 5,
  210. Nantes cedex 2,
  211. Nantes cedex 2,
  212. Neuilly sur Seine,
  213. Neuilly sur Seine,
  214. Neuilly Sur Seine,
  215. Nice cedex 2,
  216. Paris,
  217. Pessac,
  218. Saint Gregoire,
  219. Saint Priest en Jarez cedex,
  220. Saint-Herblain cedex,
  221. Strasbourg cedex,
  222. Strasbourg cedex,
  223. Strasbourg,
  224. Villejuif cedex,
  225. Villejuif,
  226. Berlin, Buch
  227. Berlin, Buch
  228. Berlin, Buch
  229. Berlin, Buch
  230. Berlin, Buch
  231. Dusseldorf,
  232. Jena,
  233. Jena,
  234. Regensburg,
  235. Regensburg,
  236. Athens, Attica
  237. Chaidari, Attica,
  238. Chaidari, Attica,
  239. Thessaloniki,
  240. Budapest,
  241. Budapest,
  242. Budapest,
  243. Budapest,
  244. Debrecen,
  245. Gyor,
  246. Pecs,
  247. Pecs,
  248. Szeged,
  249. Dublin,
  250. Dublin,
  251. Dublin,
  252. Dublin,
  253. Dublin,
  254. Haifa,
  255. Jerusalem,
  256. Petah Tiqva,
  257. Ramat Gan,
  258. Brescia, BS
  259. Meldola, FC
  260. Meldola, FC
  261. Cesena, Forlì-cesena
  262. Meldola, Forlì-cesena
  263. Lecce, LE
  264. Modena, MO
  265. Parma, PR
  266. Lugo, RA
  267. Ravenna, RA
  268. Ravenna, RA
  269. Ravenna, RA
  270. Legnago, VR
  271. Napoli,
  272. Reggio Emilia,
  273. Reggio Emilia,
  274. Nagoya, Aichi
  275. Nagoya, Aichi
  276. Kashiwa, Chiba
  277. Matsuyama, Ehime
  278. Sapporo, Hokkaido
  279. Kobe, Hyogo
  280. Natori, Miyagi
  281. Sendai, Miyagi
  282. Osaka-shi, Osaka
  283. Osakasayama, Osaka
  284. Kita-adachi-gun, Saitama
  285. Sunto-gun, Shizuoka
  286. Shimotsuke, Tochigi
  287. Chuo-ku, Tokyo
  288. Koto-ku, Tokyo
  289. Goyang-si, Gyeonggi-do
  290. Goyang-si, Gyeonggi-do
  291. Seongnam-si, Gyeonggi-do
  292. Seongnam-si, Gyeonggi-do
  293. Seongnam-si, Gyeonggi-do
  294. Seongnam-si, Gyeonggi-do
  295. Seongnam-si, Gyeonggi-do
  296. Seongnam-si, Gyeonggi-do
  297. Hwasun-gun, Jeollanam-do
  298. Seongnam-si, Gyeonggi-do,
  299. Seoul,
  300. Seoul,
  301. Seoul,
  302. Seoul,
  303. Seoul,
  304. Seoul,
  305. Seoul,
  306. Ulsan,
  307. Ulsan,
  308. Bydgoszcz,
  309. Gdansk,
  310. Gliwice,
  311. Olsztyn,
  312. Tomaszow Mazowiecki,
  313. Tomaszow Mazowiecki,
  314. Tomaszow Mazowiecki,
  315. Matosinhos, Porto
  316. Senhora da Hora, Porto
  317. Vila Nova de Gaia, Porto
  318. Vila Nova de Gaia, Porto
  319. Coimbra,
  320. Coimbra,
  321. Porto,
  322. Porto,
  323. Porto,
  324. Porto,
  325. Porto,
  326. Porto,
  327. Porto,
  328. Chelyabinsk,
  329. Moscow,
  330. Omsk,
  331. Saint-Petersburg,
  332. Saint-Petersburg,
  333. Yaroslavl,
  334. Badalona, Barcelona
  335. San Sebastian, Guipuzcoa
  336. Marbella, Malaga
  337. El Palmar, Murcia
  338. Barcelona,
  339. Barcelona,
  340. Barcelona,
  341. Barcelona,
  342. Cordoba,
  343. Girona,
  344. Jaen,
  345. Madrid,
  346. Madrid,
  347. Malaga,
  348. Salamanca,
  349. Valencia,
  350. Zaragoza,
  351. Basel, Basel-stadt
  352. Basel, Basel-stadt
  353. Basel, Basel-stadt
  354. Bellinzona, Ticino
  355. Bellinzona, Ticino
  356. Bellinzona, Ticino
  357. Lausanne, Vaud
  358. Winterthur, Zuerich
  359. Schlieren, Zurich
  360. Winterthur, Zurich
  361. Winterthur, Zurich
  362. Zurich,
  363. Zurich,
  364. Zurich,
  365. Taichung,
  366. Taichung,
  367. Taichung,
  368. Taichung,
  369. Tainan,
  370. Tainan,
  371. Taipei,
  372. Taipei,
  373. Taipei,
  374. Taipei,
  375. Taipei,
  376. Taipei,
  377. Taoyuan City,
  378. Taoyuan City,
  379. Aberdeen,
  380. Bebington,
  381. Bristol,
  382. Edinburgh,
  383. Edinburgh,
  384. London,
  385. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Official Title  ICMJE A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Brief Summary This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC CRT alone in front-line treatment of patients with locally advanced head and neck cancer.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Squamous Cell Carcinoma of the Head and Neck
Intervention  ICMJE
  • Drug: Avelumab
    Avelumab + SOC Chemoradiation
  • Other: Chemoradiation
    Cisplatin + Radiation Therapy
Study Arms  ICMJE
  • Experimental: Avelumab + SOC Chemoradiation Therapy
    • Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase
    • Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase
    • Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase
    Intervention: Drug: Avelumab
  • Placebo Comparator: Placebo + SOC CRT
    • Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase
    • Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase
    • IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase
    Intervention: Other: Chemoradiation
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: April 30, 2019)
697
Original Estimated Enrollment  ICMJE
 (submitted: October 31, 2016)
640
Estimated Study Completion Date  ICMJE June 19, 2020
Actual Primary Completion Date December 23, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

INCLUSION CRITERIA

  • Histological diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
  • HPV negative disease, Stage III, IVa, IVb; non-oropharyngeal HPV positive disease Stage III, IVa, IVb, HPV positive oropharyngeal disease T4 or N2c or N3
  • No prior therapy for advanced stage SCCHN; eligible for definitive CRT with curative intent.
  • Available tumor samples for submission or willing to undergo further tumor biopsies:
  • Age ?18 years (?19 in Korea;20 years in Japan and Taiwan).
  • ECOG Performance Status 0 or 1
  • Adequate bone marrow function
  • Adequate renal function
  • Adequate liver function
  • Pregnancy test (for patients of childbearing potential) negative at screening

EXCLUSION CRITERIA

  • Prior immunotherapy with an anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti CTLA 4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways.
  • Major surgery 4 weeks prior to randomization.
  • Prior malignancy requiring tumor-directed therapy within the last 2 years prior to enrollment, or concurrent malignancy associated with clinical instability. Exceptions for disease within the 2 years are superficial esophageal cancer (TIS or T1a) fully resected by endoscopy, prostate cancer (Gleason score 6) either curatively treated or deemed to not require treatment, ductal IS carcinoma of the breast that has completed curative treatment, adequately treated basal cell or squamous cell skin cancer.
  • Active autoimmune disease
  • Any of the following in the 6 months prior to randomization: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism.
  • Active infection requiring systemic therapy.
  • Use of immunosuppressive medication at time of randomization
  • Prior organ transplantation including allogenic stem-cell transplantation.
  • Diagnosis of prior immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
  • Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Vaccination within 4 weeks prior to randomization.
  • Current use of or anticipated need for treatment with other anti-cancer drugs.
  • Pregnant female patients, breastfeeding female patients, and male patients able to father children and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in the protocol for the duration of the study and for at least 6 months after the last dose of cisplatin and 60 days after the last dose of avelumab/placebo (whichever is later).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Austria,   Belgium,   Canada,   China,   France,   Germany,   Greece,   Hungary,   Ireland,   Israel,   Italy,   Japan,   Korea, Republic of,   Poland,   Portugal,   Russian Federation,   Spain,   Switzerland,   Taiwan,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02952586
Other Study ID Numbers  ICMJE B9991016
2016-001456-21 ( EudraCT Number )
LOCALLY ADVANCED HEAD AND NECK ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP